On November 13th, Ge Longhui reported that Beijing SL Pharmaceutical (002038.SZ) stated during a specific object survey on November 12, 2024, that the situation is expected to improve next year. In the future, the company will participate in the national centralized procurement of most new varieties listed in the past one or two years, and will not be negatively impacted by significant price reductions. It may become a new source of growth. The company's financial assets are currently at relatively low levels, and it is expected that next year's significant fluctuations in stock prices will not adversely affect the company.
双鹭药业(002038.SZ)：预计明年不会因股价大幅波动对公司产生不利影响
Beijing sl pharmaceutical (002038.SZ): It is expected that next year, the company will not be adversely affected by significant fluctuations in stock prices.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated